Evidence map›Paper›PMID 31335117›Full record

ReviewAccounts of chemical research2019

Near-Infrared Photoimmunotherapy of Cancer.

Hisataka Kobayashi, Peter L Choyke

Registry-linked trialOpen access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Accounts of chemical research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03769506 (A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 Photoimmunotherapy Versus Physician's Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of Therapy, of Which at Least One Line Must Be Systemic Therapy), which is not on this map. Cited by 248 papers.

0numbers the graph read from it
0cells of the map it votes in
248citing papers in PubMed
37.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03769506 phase3active not recruitingnot on this map

A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 Photoimmunotherapy Versus Physician's Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of Therapy, of Which at Least One Line Must Be Systemic Therapy

TypeinterventionalSponsorRakuten Medical, Inc.Ran2019 to 2025Enrolled135ConditionsHead and Neck CancerArmsASP-1929 Photoimmunotherapy, Physician's Choice SOC
3 · Its place in the literature

Who cites it

248 citing papers in PubMed, 445 citations in OpenAlex.

  1. Article
  2. Cancer theranostics.Nature reviews. Cancer · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Internalization-Dependent EGFR-Targeted Photoactivation by Cetuximab-I21 Conjugates.Journal of immunotherapy (Hagerstown, Md. : 1997) · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article

188 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Hisataka KobayashiMolecular Imaging Program, Center for Cancer Research , National Cancer Institute, National Institutes of Health , Building 10, Room B3B69, MSC1088 , Bethesda , Maryland 20892-1088 , United States.ORCID 0000-0003-1019-4112
Peter L ChoykeMolecular Imaging Program, Center for Cancer Research , National Cancer Institute, National Institutes of Health , Building 10, Room B3B69, MSC1088 , Bethesda , Maryland 20892-1088 , United States.
National Institutes of Health · US

Funding

Cancer-cell specific therapy: photo-immunotherapyZIABC011513 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KOBAYASHI, HISATAKA · 2013 to 2025
$15.5M
Intramural NIH HHS ZIA BC011513
6 · The paper itself

Abstract

This Account is the first comprehensive review article on the newly developed, photochemistry-based cancer therapy near-infrared (NIR) photoimmunotherapy (PIT). NIR-PIT is a molecularly targeted phototherapy for cancer that is based on injecting a conjugate of a near-infrared, water-soluble, silicon-phthalocyanine derivative, IRdye700DX (IR700), and a monoclonal antibody (mAb) that targets an expressed antigen on the cancer cell surface. Subsequent local exposure to NIR light turns on this photochemical "death" switch, resulting in the rapid and highly selective immunogenic cell death (ICD) of targeted cancer cells. ICD occurs as early as 1 min after exposure to NIR light and results in irreversible morphologic changes only in target-expressing cells based on the newly discovered photoinduced ligand release reaction that induces physical changes on conjugated antibody/antigen complex resulting in functional damage on cell membrane. Meanwhile, immediately adjacent receptor-negative cells are totally unharmed. Because of its highly targeted nature, NIR-PIT carries few side effects and healing is rapid. Evaluation of the tumor microenvironment reveals that ICD induced by NIR-PIT results in rapid maturation of immature dendritic cells adjacent to dying cancer cells initiating a host anticancer immune response, resulting in repriming of polyclonal CD8

Indexed as

AnimalsAntineoplastic AgentsClinical Trials as TopicDendritic CellsHumansImmunoconjugatesImmunogenic Cell DeathImmunotherapyInfrared RaysMiceNeoplasmsPhotosensitizing AgentsPhototherapyAntineoplastic AgentsImmunoconjugatesPhotosensitizing Agents

Identifiers

PMID31335117
PMCPMC6704485
OpenAlexW2964086043

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.